Share Capital
Number of Shares and Potential Voting Rights of Innogenetics (update: November 3, 2008)
| Total outstanding shares: effective voting rights attached to shares representing the capital (DENOMINATOR) |
30,878,920
|
| Future, potential or not, voting rights resulting from rights and commitments at the conversion into or the subscription for shares to be issued (exercise of granted warrants) |
668,780
|
| Future, potential or not, voting rights resulting from rights and commitments at the conversion into or the subscription for shares to be issued (conversion of granted bond) |
3,086,660
|
| Total shares and potential voting rights |
34,634,360
|
History of Share Capital (number of outstanding shares)
Over the last three years, the share capital of Innogenetics increased due to:
- The exercise of warrants granted under warrant plans that were adopted by the Extraordinary Shareholders' Meeting of October 25, 1996 for employees of the Company and certain key consultants;
- A private placement on March 31, 2005 of 2 730 000 new shares; and
- A private placement on October 19, 2005 with Global Opportunities Capital Asset Management BV of 827 300 new shares.
|
Date
|
Share capital increase (in €)
|
Share capital
(in €)
|
Number of shares
|
Share capital
value per share
(in €)
|
| January 1, 2005 |
|
17 161 098.59
|
27 317 596
|
0.6282
|
| February 1, 2005 |
1 522.16
|
17 162 620.75
|
27 320 019
|
0.6282
|
| March 31, 2005 |
1 714 986.00
|
18 877 606.75
|
30 050 019
|
0.6282
|
| August 9, 2005 |
728.73
|
18 878 335.48
|
30 051 179
|
0.6282
|
| October 19, 2005 |
519 709.86
|
19 398 045.34
|
30 878 479
|
0.6282
|
| February 2, 2006 |
277.04
|
19 398 322.38
|
30 878 920
|
0.6282
|
Authorized Capital
At the Extraordinary Shareholders’ Meeting of June 25, 2007, the Shareholders’ Meeting conferred the right upon the Board of Directors to increase the share capital of Innogenetics by an amount of €19 398 322.38. The authorization expires on the fifth anniversary of the date of publication in the Belgian Official Gazette of the resolution of June 25, 2007.
The increase of capital in the framework of the authorized capital can be realized through the issuance of shares, the issuance of convertible bonds, and/or warrants.
On the occasion of a capital increase within the framework of the authorized capital, the Board of Directors is entitled to cancel or restrict the preferential subscription rights of the existing shareholders in general, or for the benefit of one or more named persons.
Innogenetics’ capital management objective is to ensure the Company’s ability to continue as a going concern.